An Insider's View On CDMO Services For Biologics

If you've had conversations at any major industry conference lately, you already know what's keeping biopharma teams up at night: timelines, regulatory complexity, and supply chain reliability. What's useful here is hearing it framed directly by Maider Parikh, Ph.D., Vice President of Commercial Operations for Biologics at Thermo Fisher Scientific, who gathered those insights firsthand from customers at this year's BIO International Convention.

Parikh identifies four core pressure points: schedule adherence in a fast-moving regulatory environment, navigating nuanced compliance requirements, securing reliable supply chains, and handling molecule-specific technical challenges that demand specialized knowledge. None of these are new problems, but the intensity is real, and customers are leaning harder on their contract development and manufacturing organization (CDMO) partners to carry more of the burden.

Thermo Fisher's response centers on global multi-site capacity, integrated drug substance and drug product capabilities, and technologies including single-use bioreactors, high-throughput screening, and automated fill-finish systems. The picture that emerges is one of a CDMO built for complexity, not just volume.

Access the full Q&A to evaluate how these capabilities map to your current program needs.